Business Collaboration Agreement for exploring Entry into Nucleic Acid Drug CDMO Business

July 12^th, 2024

We are pleased to announce that Hokkaido System Science Co., Ltd. (HSS), having a headquarters in Sapporo, Hokkaido (CEO: Yukio Mizutani) has signed a business collaboration agreement with Mitsubishi Gas Chemical Company, Inc. (MGC), having a headquarters in Chiyoda-ku, Tokyo (President: Masashi Fujii) to jointly explore entry into nucleic acid drug CDMO (Contract Development and Manufacturing Organization) business.

HSS has engaged in synthesis and sales of nucleic acids for research use for more than 30 years. Based on such accumulated know-how about nucleic acid synthesis, and together with MGC’s analytical technology and knowledge of Good Manufacturing Practice (GMP), we will aim to launch a nucleic acid drug CDMO business to provide solutions for stakeholders including academic researchers.